Your browser doesn't support javascript.
loading
Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
Kawakami, Hisato; Sunakawa, Yu; Inoue, Eisuke; Matoba, Ryo; Noda, Kenta; Sato, Toshiyuki; Suminaka, Chihiro; Yamaki, Mami; Sakamoto, Yasuhiro; Kawabata, Ryohei; Ishiguro, Atsushi; Akamaru, Yusuke; Kito, Yosuke; Yabusaki, Hiroshi; Matsuyama, Jin; Takahashi, Masazumi; Makiyama, Akitaka; Hayashi, Hidetoshi; Chamoto, Kenji; Honjo, Tasuku; Nakagawa, Kazuhiko; Ichikawa, Wataru; Fujii, Masashi.
Afiliação
  • Kawakami H; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-sayama, Osaka 589-8511, Japan. Electronic address: kawakami_h@med.kindai.ac.jp.
  • Sunakawa Y; Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511, Japan.
  • Inoue E; Showa University Research Administration Center, Showa University, Tokyo 142-8555, Japan.
  • Matoba R; DNA Chip Research Inc., Tokyo 105-0022, Japan.
  • Noda K; Sysmex Corporation, Kobe, Hyogo 651-2271, Japan.
  • Sato T; Sysmex Corporation, Kobe, Hyogo 651-2271, Japan.
  • Suminaka C; Sysmex Corporation, Kobe, Hyogo 651-2271, Japan.
  • Yamaki M; Sysmex Corporation, Kobe, Hyogo 651-2271, Japan.
  • Sakamoto Y; Department of Medical Oncology, Osaki Citizen Hospital, Osaki, Miyagi 989-6183, Japan.
  • Kawabata R; Department of Surgery, Osaka Rosai Hospital, Sakai, Osaka 591-8025, Japan.
  • Ishiguro A; Department of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Hokkaido 006-8555, Japan.
  • Akamaru Y; Department of Surgery, Ikeda City Hospital, Ikeda, Osaka 563-8510, Japan.
  • Kito Y; Department of Medical Oncology, Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa 920-8530, Japan.
  • Yabusaki H; Department of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata, Niigata 951-8566, Japan.
  • Matsuyama J; Department of Gastroenterological Surgery, Higashiosaka City Medical Center, Higashiosaka, Osaka 578-8588, Japan.
  • Takahashi M; Division of Gastroenterological Surgery, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa 221-0855, Japan.
  • Makiyama A; Cancer Center, Gifu University Hospital, Gifu, Gifu 501-1194, Japan.
  • Hayashi H; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-sayama, Osaka 589-8511, Japan.
  • Chamoto K; Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto 606-8501, Japan.
  • Honjo T; Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto 606-8501, Japan.
  • Nakagawa K; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-sayama, Osaka 589-8511, Japan.
  • Ichikawa W; Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Kanagawa 227-8501, Japan.
  • Fujii M; Department of Digestive Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Eur J Cancer ; 184: 10-20, 2023 05.
Article em En | MEDLINE | ID: mdl-36889037
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Nivolumabe Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Nivolumabe Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article